Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the consistency between pathologic immunohistochemistry assay and flow immunotyping of patients with lymphoma cell leukemia.
Methods: The immunohistochemistry and flow immunotyping data of 31 patients with non-hodgkin lymphoma admitted in our hospital from January 2012 to December 2018 were analyzed retrospectively. The pathologic immunohistochemical expression of lymphatic cells was compared with that of flow immunotyping types, and the change of expression rate of various antigens in the progression of lymphomas into leukemia stage was studied. The characteristics of immune typing and pathologic immunohistochemistry of lymphoblastic leukemia, and their diagnostic value in lymphoblastic leukemia was observed.
Results: All patients with lymphoma reached the leukemia stage. The results of flow immunotyping were basically consistent with the results of pathological immunohistochemistry. The pathological immunohistochemistry showed that CD5, CD3, CD99, CD7, CD34, CD43, etc. mainly expressed in the patients with T lymphocyte lymphoma leukemia, of which CD5 showed the highest expression rate and its positive rate was 100%. The flow immunotyping showed that CD7, CD3, CD2, CD5, CD11b, CD34 and HLA-DR was mainly expressed in the patients with T lymphocyte lymphoma leukemia, of which CD7 was the most sensitive and its positive rate was 100 %. Although the antigens expressed in the pathologic immunohistochemistry and flow immunotyping were basically consistent, there were differences in the expression rates of various antigens, CD20, CD79a, BCL-2, CD10, and the Hodgkin's lymphoma cell antigen PAX5 derived from B cells them mainly expressed in BLL patients assay by pathological immunohistochemistry, among the expression rate of CD20 was 100%, which was higher than other antigen expression rate. CD19, CD20, CD22, CD79a, skappa, and early antigen HLA-DR mainly expressed in BLL patients assayed by flow immunotyping, among them CD19 showed a positive rate of 94.7%. The results of immunohistochemistry and flow immunotyping were compared, it was found that 42% of the patients were accompanied by CD20 expression loss, and the survival period of these patients was significantly reduced.
Conclusion: 25% of patients with T-lymphoma leukemia are accompanied by CD3 expression loss, and 42% of patients with B-cell lymphoma leukemia are accompanied by CD20 expression loss. There is no significant change in survival of T-cell lymphoma leukemia patients with CD3 expression loss, however, the survival period of B-cell lymphoma leukemia patients with CD20 expression loss is significantly shortened.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.05.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel perceptions and insights into the rare hematologic malignancy of acute megakaryocytic leukemia: a multicenter clinical retrospective study.
Front Med (Lausanne)
June 2025
Department of Pathology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Objective: Acute megakaryocytic leukemia (AMKL) constitutes a rare subtype of acute myeloid leukemia in clinical practice and exhibits a high degree of heterogeneity. This study endeavors to explore the clinical manifestations, diagnosis, treatment, and prognosis of AMKL, offering novel perspectives for both basic and clinical investigations of rare myeloid tumors in the fields of oncology and hematology.
Methods: The clinical data of 23 patients with AMKL admitted to the Fujian Medical University Union Hospital, the Affiliated Hospital of Putian University, and the First Affiliated Hospital of Gannan Medical University from January 2014 to July 2024 were retrospectively analyzed.
Peripheral immune profiling of soft tissue sarcoma: perspectives for disease monitoring.
Front Immunol
November 2024
Center for Neurosciences and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, Coimbra, Portugal.
Studying the tumor microenvironment and surrounding lymph nodes is the main focus of current immunological research on soft tissue sarcomas (STS). However, due to the restricted opportunity to examine tumor samples, alternative approaches are required to evaluate immune responses in non-surgical patients. Therefore, the purpose of this study was to evaluate the peripheral immune profile of STS patients, characterize patients accordingly and explore the impact of peripheral immunotypes on patient survival.
View Article and Find Full Text PDFDetection of >400 Cluster of Differentiation Biomarkers and Pathway Proteins in Single Immune Cells by Cyclic Multiplex Tagging for Single-Cell Proteomic Studies.
Anal Chem
October 2024
Multiplex Biotechnology Laboratory, Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, United States.
Article Synopsis
- The study focuses on identifying and characterizing immune cell subpopulations, which is crucial for understanding immune development and responses to environmental factors.
- The newly introduced single-cell cyclic multiplex tagging (CycMIST) technology allows for the simultaneous measurement of over 400 proteins, far surpassing current methods in multiplex capacity.
- The CycMIST technology has been validated against established techniques and provides insights into T cell activation and protein interactions, potentially aiding in understanding immune responses in various diseases.
Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.
Clin Cancer Res
December 2024
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Article Synopsis
- Malignant peripheral nerve sheath tumors (MPNST) pose a significant risk to patients with neurofibromatosis type 1 (NF1), with current treatments failing to improve outcomes, highlighting the need for new therapies that target the tumor's immune environment.
- Researchers examined the immune microenvironment in NF1-associated tumors, using various techniques to analyze how immune cells infiltrate and respond to these tumors.
- Results showed that malignant progression involved increased infiltration of specific immune cells, particularly tumor-associated macrophages, linked to worse patient outcomes, indicating a potential for therapies that can enhance anti-tumor immune responses.
Acute myeloid leukemia with fusion gene: 'Pitfalls' in diagnosis.
Hematology
December 2024
Department of Clinical Laboratory, Fuyang People's Hospital, Fuyang, People's Republic of China.
Article Synopsis
- The text discusses a rare case of acute myeloid leukemia (AML) associated with basophilia, emphasizing the challenges in diagnosing this condition due to its rarity and poor prognosis.
- The authors describe their use of various diagnostic methods, including morphological screening, immunotyping, FISH analysis, and RNA sequencing, to accurately identify the type of AML and to guide treatment decisions.
- The study highlights the importance of advanced techniques such as NGS for detecting a broader range of genetic mutations, which can help avoid misdiagnosis and improve treatment outcomes for patients with hematologic malignancies.